Welcome to our dedicated page for Haleon SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Haleon’s separation from GSK created a consumer-health giant with dozens of power brands—and a web of disclosures that can overwhelm even seasoned analysts. Sales are broken out across oral care, pain relief, vitamins and more, while its first standalone Form 20-F runs hundreds of IFRS-heavy pages. If you have ever asked, "Where do I find Haleon insider trading Form 4 transactions" or "How do I decode Haleon’s quarterly earnings report 10-Q filing?", you know the challenge.
Stock Titan solves it. Our AI reads every new filing the moment it hits EDGAR, then delivers plain-English summaries, red-flags and searchable key terms. Whether you need Haleon Form 4 insider transactions in real-time, a side-by-side view of segment revenue from the latest 6-K, or want Haleon SEC filings explained simply, the platform highlights what matters: advertising spend trends, litigation provisions, post-spin debt covenants and more. Long-tail queries such as "Haleon executive stock transactions Form 4", "understanding Haleon SEC documents with AI", or "Haleon earnings report filing analysis" resolve to the exact section—no scrolling required.
All filing types are here, updated continuously: the Haleon annual report 10-K simplified (20-F), Haleon proxy statement executive compensation, and every Haleon 8-K material events explained. Use our tools to:
- Track insider buying and selling before marketing launches
- Compare vitamin and mineral supplement growth quarter-over-quarter
- Spot supply-chain disclosures in material event filings
Haleon plc announced the purchase and cancellation of 175,642 ordinary shares of of each as part of the second tranche of its share buyback programme announced on 31 July 2025. After settlement, Haleon registered share capital stands at 8,970,696,108 ordinary shares of each, of which 3,880,205 are held as treasury shares, leaving 8,966,815,903 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided link and on the Company's investor website. This announcement relates solely to the executed tranche of the buyback programme and the resulting share capital figures.
Haleon plc announced the purchase and cancellation of 930,345 ordinary shares under the second tranche of its buyback programme. Reported trade prices ranged between £360.90 and £367.00 with a reported volume-weighted average price of £363.4411. After settlement the company states its registered share capital is 8,970,871,750 ordinary shares, of which 3,880,205 are held as treasury, leaving 8,966,991,545 ordinary shares with voting rights. The announcement points shareholders to a full trade breakdown and notes the release does not constitute an offer for securities.
Haleon plc filed a Form 6-K publishing a TR-1 notification showing major holdings in the Company. The notice reports 423,379,327 direct voting rights (4.72%) and additional financial instruments totaling 26,420,926 voting rights plus equity swaps of 193,460 rights, amounting to 5.01% of voting rights through financial instruments. The disclosure identifies Wellington Management Group LLP and related controlled undertakings as the reporting chain that holds the 5.01% position. The TR-1 was published around 19-20 August 2025 and includes nominee holdings and a full chain of controlled undertakings for the reporting entity.
Haleon plc reports the purchase and cancellation of 1,504,400 ordinary shares of each under the second tranche of its share buyback programme announced 31 July 2025. Trades executed on 18 August 2025 via London Stock Exchange CBOE (UK)/CXE at an average price of 358.0459 per share. After settlement, registered share capital is 8,971,802,095 ordinary shares, with 3,880,205 held as treasury shares, leaving 8,967,921,890 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided RNS link and on the company website.
Haleon plc reports the purchase and cancellation of 1,600,000 ordinary shares of £0.01 each as part of the second tranche of its buyback programme announced 31 July 2025. After settlement, registered share capital is 8,973,306,495 ordinary shares, with 3,880,205 held as treasury shares, leaving 8,969,426,290 voting ordinary shares. A full breakdown of individual trades is available via the provided RNS link and on the Company website. The announcement states it does not constitute an offer for securities.
Haleon plc announced the purchase and cancellation of 1,399,293 ordinary shares of each under the second tranche of its share buyback programme announced 31 July 2025. Trades executed on 14 August 2025 on the London Stock Exchange/CBOE UK totalled 1,399,293 shares at an average price of 58.7136. After settlement, registered share capital is 8,974,906,495 ordinary shares, of which 3,880,205 are treasury shares, leaving 8,971,026,290 ordinary shares with voting rights for disclosure threshold purposes. A full trade breakdown is available via the provided RNS link and the company's investor website.
Haleon has completed a tranche of its announced share buyback, purchasing 830,000 ordinary shares for cancellation on 13 August 2025 at a volume-weighted average price of 356.7308p. The purchases on the London Stock Exchange ranged between 354.7000p and 358.6000p.
After settlement the company reports a registered share capital of 8,976,305,788 ordinary shares, of which 3,880,205 are held in treasury, leaving 8,972,425,583 voting shares. A full trade breakdown is available from the company’s announcement link and on its investor website.
Haleon plc announced the purchase and cancellation of 1,400,000 ordinary shares of \u00A3 .01 each under the second tranche of its buyback programme. The purchases occurred on 12 August 2025 on the London Stock Exchange with a highest price of 356.1000p, lowest of 353.2000p and a volume weighted average price of 354.8037p.
After settlement the company reports registered share capital of 8,977,135,788 ordinary shares, of which 3,880,205 are held as treasury shares, leaving 8,973,255,583 ordinary shares with voting rights. The announcement includes a breakdown of individual trades under the Market Abuse Regulation and provides links for shareholders to verify holdings for FCA notification thresholds.
Haleon plc disclosed director/PDMR share transactions showing that two senior officers participated in the company's Share Reward Plan. Adrian Morris (General Counsel) and Tamara Rogers (Chief Marketing Officer) each acquired 36 Partnership Shares at £3.563199 per share and were awarded 36 Matching Shares at nil cost, for an aggregated 72 shares each. The transactions occurred on 11 August 2025 on the London Stock Exchange and were announced by the company, reflecting routine compensation-related share acquisitions under its Share Reward Plan.
Haleon plc purchased 1,200,000 ordinary shares of £0.01 each for cancellation under the second tranche of its share buyback programme announced 31 July 2025. Purchases took place on 11 August 2025 on the London Stock Exchange with a highest price of 357.0000p, lowest price of 352.2000p and a volume-weighted average price of 354.2107p. After settlement, registered share capital is 8,978,535,788 ordinary shares, with 3,880,205 held as treasury, leaving 8,974,655,583 ordinary shares with voting rights. A full trade breakdown is published via the provided RNS link and on the company's investor website; the announcement states it does not constitute an offer.
FAQ
What is the current stock price of Haleon (HLN)?
What is the market cap of Haleon (HLN)?
